JMJD3 Exerts Oncorepressor Activity in Acute Promyelocytic Leukemia by Promoting PU.1 Expression

All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) has been the most famous differentiation induction therapy during which the expression of PU.1, a key transcription factor (TF) for myeloid lineage determination in normal hematopoiesis is restored. In our previous studies, we foun...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology (New York) 2023-08, Vol.57 (4), p.653-660
Main Authors: Wang, Meng-Xi, Yu, Shan-He, Xiao, Min, Chen, Juan
Format: Article
Language:English
Subjects:
Acute promyeloid leukemia
Biochemistry
Biomedical and Life Sciences
Hemopoiesis
Human Genetics
Induction therapy
Life Sciences
Molecular Biology of the Cell
Myelopoiesis
Promyeloid leukemia
PU.1 protein
Retinoic acid
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) has been the most famous differentiation induction therapy during which the expression of PU.1, a key transcription factor (TF) for myeloid lineage determination in normal hematopoiesis is restored. In our previous studies, we found a stress-inducible H3K27 demethylase, JMJD3, to directly upregulate PU.1 expression to promote myeloid commitment during normal myelopoiesis. In addition, JMJD3 acts as an oncorepressor and plays a critical regulatory role in the initiation and progression of malignant hematopoiesis. In this study, we further resolved the relationship between JMJD3 and PU.1 in APL therein JMJD3 exerts oncorepressor activity via promoting PU.1 expression.
ISSN:0026-8933
1608-3245
DOI:10.1134/S0026893323040179